Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against the other stocks that will bounce back.

Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments. The S&P 500 rose by 0.43%, while the tech-heavy Nasdaq added 0.27%. The blue-chip Dow Jones Industrial Average increased by 0.7%

READ ALSO: 11 Best Stocks Under $15 to Buy According to Hedge Funds and 10 Most Profitable Cheap Stocks to Buy Now.

As anticipated, the Federal Open Market Committee decided to keep its benchmark overnight borrowing rate unchanged in a range between 4.25% to 4.5%, where it has been since December.

In its post-meeting statement, the Fed pointed out that the risks of both higher unemployment and higher inflation have risen. The Fed also said that uncertainty about the economic outlook has grown and that it will keep watching new data closely before making any changes. This announcement coincides with growing concerns about a global trade war that could send prices higher. This could make it difficult for the central bank to achieve its goal of bringing inflation down to 2%.

During the post-decision press conference, Fed Chair Jerome Powell stated that if the recently announced large increases in tariffs remain in place, they could slow economic growth, push inflation up in the long run, and increase unemployment.

Bloomberg reported on Wednesday that the Trump administration aims to end trade restrictions on AI. This helped boost some AI and tech stocks. However, earlier on Wednesday, President Trump told reporters that he is not ready to lower tariffs on China as a condition to start trade talks. This statement by the US President came ahead of meetings set to take place this weekend between US and Chinese officials in Switzerland to discuss trade issues.

Methodology

To compile our list of the 11 stocks that will bounce back according to analysts, we looked for stocks that have lost at least 30% year-to-date as of May 5, 2025. Next, we focused on the top stocks that analysts believe have the most potential for growth. To find stocks that will bounce back, we narrowed down our selection by looking for stocks that analysts believe will gain at least twice as much as they have lost year-to-date. Finally, we ranked the 11 stocks that will bounce back based on their average price target upside potential according to analysts as of May 5, 2025.

Additionally, we mentioned the hedge fund sentiment surrounding each stock, which was taken from Insider Monkey’s Q4 2024 database of more than 1,000 elite hedge funds.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Biohaven Ltd. (NYSE:BHVN)

Year-to-Date Performance: -39.32%

Average Price Target Upside Potential According to Analysts: 160.83%

Number of Hedge Fund Holders: 41

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company. It focuses on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven Ltd. (NYSE:BHVN) ranks among stocks that will bounce back according to analysts.

Leerink Partners analyst Marc Goodman has kept a positive outlook on Biohaven Ltd. (NYSE:BHVN) by maintaining a “Buy” rating on April 28. The analyst believes that the company is working strategically to expand its market by pursuing approval of troriluzole for the treatment of patients with spinocerebellar ataxia (SCA) in the EU, even though the review process can be challenging and the current financial models do not include sales outside of the US. Goodman acknowledges the company’s strong commitment to expand and is also optimistic about the drug’s chances for approval in the US. The US Food and Drug Administration (FDA) accepted to review the New Drug Application (NDA) for troriluzole, the decision for which is expected in the third quarter of 2025. If approved, Biohaven Ltd. (NYSE:BHVN) will be ready to commercialize troriluzole for SCA in the US in 2025.

Overall, BHVN ranks 4th on our list of stocks that will bounce back according to analysts. While we acknowledge the potential of BHVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BHVN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.